|
Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis |
Bachelot T, McCool R, Duffy S, Glanville J, Varley D, Fleetwood K, Zhang J, Jerusalem G |
|
|
Record Status This is a systematic review that meets the criteria for inclusion on DARE. Bibliographic details Bachelot T, McCool R, Duffy S, Glanville J, Varley D, Fleetwood K, Zhang J, Jerusalem G. Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis. Breast Cancer Research and Treatment 2014; 143(1): 125-133 Indexing Status Subject indexing assigned by NLM MeSH Androstadienes /administration & Antineoplastic Combined Chemotherapy Protocols /therapeutic use; Aromatase Inhibitors /administration & Breast Neoplasms /drug therapy /metabolism /mortality /pathology; Clinical Trials as Topic; Disease Progression; Estradiol /administration & Everolimus; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sirolimus /administration & Treatment Outcome; derivatives; derivatives; dosage; dosage /analogs & dosage /analogs & dosage /therapeutic use AccessionNumber 12013069601 Date bibliographic record published 20/12/2013 |
|
|
|